Cargando…

Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma

Detalles Bibliográficos
Autores principales:	Willrich, Maria Alice V., Murray, David L., Rajkumar, S. Vincent, Bryant, Sandra C., Larson, Dirk, Pazdernik, Vanessa, Snyder, Melissa R., Kyle, Robert A., Dispenzieri, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440004/ https://www.ncbi.nlm.nih.gov/pubmed/36055996 http://dx.doi.org/10.1038/s41408-022-00722-5

Ejemplares similares

Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies
por: Kumar, Shaji, et al.
Publicado: (2019)

Light chain myeloma and detection of free light chains in serum and urine of dogs and cats
por: Harris, Robert Adam, et al.
Publicado: (2021)

Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response to Therapy
por: Moustafa, Muhamad Alhaj, et al.
Publicado: (2015)

Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma
por: Claveau, Jean-Sébastien, et al.
Publicado: (2022)

Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio
por: Szabo, Agoston Gyula, et al.
Publicado: (2021)

Multiple myeloma: Detection of free monoclonal light chains by modified immunofixation electrophoresis with antisera against free light chains
por: Wilhite, Dorian, et al.
Publicado: (2021)

Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies
por: Tietsche de Moraes Hungria, Vania, et al.
Publicado: (2016)

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
por: Lopez-Anglada, Lucia, et al.
Publicado: (2018)

Analytical and clinical concordance of free light chain assay
por: Smith, Andrew, et al.
Publicado: (2018)

Mutations in Specific Structural Regions of Immunoglobulin Light Chains Are Associated with Free Light Chain Levels in Patients with AL Amyloidosis
por: Poshusta, Tanya L., et al.
Publicado: (2009)

Advanced isolated light chain amyloid cardiomyopathy with negative immunofixation and normal free light chain ratio
por: Zach, David, et al.
Publicado: (2021)

Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients
por: Sprangers, Ben, et al.
Publicado: (2020)

Serum Free Light Chain Only Myeloma with Cytoplasmic IgM
por: Ebana, Hideaki, et al.
Publicado: (2014)

Serum free light chains and multiple myeloma: Is it time to extend their application?
por: Markovic, Uros, et al.
Publicado: (2020)

Role of serum‐free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma
por: Tacchetti, Paola, et al.
Publicado: (2022)

Multiple myeloma with acute light chain cast nephropathy
por: Leung, Nelson, et al.
Publicado: (2023)

Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients
por: García de Veas Silva, José Luis, et al.
Publicado: (2016)

Silver Nanoparticle-Based Assay for the Detection of Immunoglobulin Free Light Chains
por: Lizoń, Anna, et al.
Publicado: (2019)

Verification study of free light chains assays on reagent-optimized analysers
por: Šegulja, Dragana, et al.
Publicado: (2019)

Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma
por: Schieferdecker, Aneta, et al.
Publicado: (2020)

Evaluation of Correlation between Serum Free Light-Chain Assay and Bone Marrow Study in Multiple Myeloma Patients
por: Zamani, Fatemeh, et al.
Publicado: (2021)

Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement
por: Hegen, Harald, et al.
Publicado: (2022)

The clinical utility of serum free light chain and heavy/light chain assays in monitoring disease activity in patients with IgG myeloma after achieving a deep response
por: Shimizu, Kazuyuki, et al.
Publicado: (2017)

A case of light chain deposition disease involving the kidney with a normal serum free kappa/lambda light chain ratio
por: Zhang, Suojian, et al.
Publicado: (2022)

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
por: Yadav, Punit, et al.
Publicado: (2018)

Early Normalization of Free Light Chains Predicts Better Outcomes in Patients with Multiple Myeloma
por: Benson, Rony, et al.
Publicado: (2020)

Serum Free Light Chains in Neoplastic Monoclonal Gammopathies: Relative Under-Detection of Lambda Dominant Kappa/Lambda Ratio, and Underproduction of Free Lambda Light Chains, as Compared to Kappa Light Chains, in Patients With Neoplastic Monoclonal Gammopathies
por: Lee, Won Sok, et al.
Publicado: (2018)

A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis
por: Sharpley, Faye A., et al.
Publicado: (2019)

Light chain deposition disease with low glomerular proteinuria and multiple myeloma: If you search you find
por: Gobbi, Laura, et al.
Publicado: (2021)

N-Glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression
por: Dispenzieri, Angela, et al.
Publicado: (2020)

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial
por: Klein, Eva-Maria, et al.
Publicado: (2021)

Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study
por: Markovic, Uros, et al.
Publicado: (2021)

Disease spectrum of abnormal serum free light chain ratio and its diagnostic significance
por: Xu, Bin, et al.
Publicado: (2017)

Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure
por: Hutchison, Colin A, et al.
Publicado: (2008)

Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements
por: Dejoie, Thomas, et al.
Publicado: (2018)

Serum free light chain level at diagnosis in myeloma cast nephropathy—a multicentre study
por: Yadav, Punit, et al.
Publicado: (2020)

Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis
por: Hegen, Harald, et al.
Publicado: (2022)

P900: INVOLVED/UNINVOLVED SERUM FREE LIGHT CHAIN RATIO IS A STRONGER PREDICTOR OF DIAGNOSTIC/RISK FACTORS IN LIGHT CHAIN COMPARED TO HEAVY CHAIN MONOCLONAL GAMMOPATHIES
por: Thorir Oskarsson, Jon, et al.
Publicado: (2023)

Immunoglobulin Free Light Chain Dimers in Human Diseases
por: Kaplan, Batia, et al.
Publicado: (2011)

Saliva Free Light Chains in Patients with Neuro-Sjögren
por: Konen, Franz Felix, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bv834gcre9ceto39k3b4fluntj